Overview:
Heart failure, often called as Congestive Heart Failure (CHF), is a chronic, progressive condition in which the heart is incapable to pump blood. There are two types of heart failure namely, left-sided heart failure and right-sided heart failure. Left-sided heart failure further bifurcates into systolic failure and diastolic failure. Systolic heart failure (Heart Failure with reduced Ejection Fraction (HFrEF)) is the condition when the left ventricle is unable to contract normally and is extremely weak to pump sufficient blood around the body. Diastolic failure or Heart Failure with preserved Ejection Fraction (HFpEF) occurs when the left ventricle is very stiff, cannot relax, and unable to fill with blood normally. On the other side, right-sided heart failure is also known as Right Ventricular (RV) heart failure generally occurs consequent to left-sided failure, as the rising fluid pressure through the lungs damages the right side of heart.
Growing geriatric population coupled with rising prevalence of heart failure across the world are expected to drive the market growth over the forecast period. In addition, commercialization of new or innovative drugs and rising per capita healthcare expenditure across the globe are likely to nurture the growth of this vertical. As per data published by the World Health Organization (WHO), worldwide population aged 60 years and above is anticipated to surge from 841.0 million in 2013 to more than 2.0 billion by 2050. This population is prone to develop chronic diseases such as heart failure and diabetes. According to statistics published by the European Society of Cardiology, the number of people suffering from heart failure around the world increased from 23.0 million in 2010 to 26.0 million 2017, which is further anticipated to rise by 46.0% by 2030.
The Angiotensin II Receptor Blockers (ARBs) segment is expected to spearhead the market during the forecast period owing to rising demand for sacubitril/valsartan combination and metoprolol for the treatment of heart failure. Administration of ARBs in heart failure decreases the risk of death and reduces the chances of hospitalization. Among the distribution channels, hospital pharmacies segment is expected to dominate the market due to increasing hospitalization leading to rising heart failure drugs procurement in hospital pharmacies.
North America is expected to hold substantial market share over the forecast period attributed to growing geriatric population and changing lifestyle leads to develop Cardiovascular Diseases (CVDs) such as heart failure, obesity, and diabetes. Europe is expected to follow North America in terms of value due to flourishing pharmaceutical industries in the U.K., Germany, France, and other European countries.
The established presence of generic drugs and patented drugs manufacturers across the globe is supporting the growth of the heart failure drugs market. Novartis AG’s Entresto tablets, a combination of sacubitril & valsartan and Amgen Inc.’s Corlanor (ivabradine) tablets are the most remarkable drugs for heart failure treatment.
The global heart failure drugs market is segmented on the following bases:
Key players identified in the global heart failure drugs market include:
This report offers:
